Posted by Michael Wonder on 02 Mar 2020
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
28 February 2020 - CHMP of the EMA has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease in adults.
In September, the U.S. FDA approved nintedanib as the first and only medicine to slow the rate of decline in pulmonary function in adults living with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan and Brazil.
